Abstract:Background: As a cause of respiratory tract infections in humans, influenza remains with high morbidity and mortality, with associated significant healthcare burden and increased financial burden. Traditional Chinese medicine injections (TCMIs) combined with oseltamivir (TCMIs + oseltamivir) are the representative therapeutic strategies for influenza, which is a compliant with clinical applications in China. The aim of this study was to describe the comparative efficacy and safety of TCMIs + oseltamivir in patients with influenza, based on the current evidence. Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, VIP information resource integration service platform databases, and the Chinese biomedical literature service system were searched to find randomized controlled trials where TCMIs + oseltamivir are the representative therapeutic strategies for influenza, from inception until October 2021, without language restriction. Two investigators independently screened eligibility criteria, extracted data, and appraised the risk of bias with the same criteria. We conducted a network meta-analysis using the Bayesian random method for each outcome and performed the sensitivity analysis, meta-regression, and Egger’s and Begg’s tests for the reliability and robustness of our results. Results: Thirty-one trials including 2,893 participants proved eligible and reported on four TCMIs + oseltamivir versus oseltamivir. Network meta-analysis showed Yanhuning (YHN) +oseltamivir (MD = −1.7, 95% CrI: −2.5 to −0.88; SUCRA = 0.89; low certainty of evidence) in fever disappearance time, Tanreqing (TRQ) +oseltamivir (MD = −1.9, 95% CrI: −2.8 to −1; SUCRA = 0.97; low certainty of evidence) in cough disappearance time, and Xiyanping (XYP) +oseltamivir (OR = 5.9, 95% CrI: 3.1 to 11; SUCRA = 0.82; very low certainty of evidence) in the response rate to be more efficacious than oseltamivir alone with the best SUCRA. Based on the combined SUCRA value for primary outcomes, TRQ + oseltamivir is probably better in cough disappearance time, and XYP + oseltamivir and YHN + oseltamivir may be better in fever disappearance time than others. No significant difference in safety between the treatments. Conclusion: In patients with influenza, TCMIs + oseltamivir only partially improve flu symptoms. Overall therapeutic efficacy and safety are inconclusive, based on low to very low certainty of evidence. However, the safety remains uncertain, and TCMI treatments for influenza should be considered with caution. More high-quality studies examining the efficacy and safety of TCMIs are needed. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42021286994

Studies on Efficacy and Safety of Inhalation Zanamivir Treatment for Influenza Patients

Influenza A-associated Severe Pneumonia in Hospitalized Patients: Risk Factors and NAI Treatments.

An Uncontrolled Open-Label, Multicenter Study to Monitor the Antiviral Activity and Safety of Inhaled Zanamivir (as Rotadisk Via Diskhaler Device) among Chinese Adolescents and Adults with Influenza-Like Illness.

Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study

A Multicentre, Randomized, Controlled Trial of Oseltamivir in the Treatment of Influenza in a High-Risk Chinese Population

A Multicenter Randomized Controlled Study of the Efficacy and Safety of Oseltamivir in the Treatment of Influenza in a High Risk Population

Clinical Study on Oseltamivir Treating Suspected Influenza Patients

Clinical Analysis of Severe Influenza A/H1N1 in 53 Patients

Inhibitory Effects and Related Molecular Mechanisms of Huanglian-Ganjiang Combination Against H1N1 Influenza Virus

Clinical efficacy and safety of peramivir trihydrate sodium chloride injection in the treatment of acute simple uncomplicated influenza

A Study on the Efficacy and Safety of Oseltamivir in the Treatment of Suspected Influenza Patients

A randomized controlled study of peramivir, oseltamivir and placebo in patients with mild influenza

Clinical characteristics and outcomes during a severe influenza season in China during 2017-2018.

Efficacy and safety of Lianhua Qingwen as an adjuvant treatment for influenza in Chinese patients: A meta-analysis

Traditional Chinese Medicine Injections Combined With Oseltamivir for Influenza: Systematic Review and Network Meta-Analysis

A Randomized and Controlled Clinical Evaluation of Oseltamivir in the Treatment of Influenza

Clinical Efficacy and Safety of Chinese Patent Medicine Combined with Oseltamivir for the Treatment of Adult Influenza: A Systematic Review and Meta-Analysis

Mixture prepared with Chinese medicines in terms of releasing exterior cold and clearing interior heat: its efficacy and safety in patients with seasonal influenza-a randomized controlled trial

Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study

Efficacy and Safety of ZX-7101A, an Inhibitor of Influenza Cap-Dependent Endonuclease, in Adults with Uncomplicated Influenza: a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Trial.

Study on the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A